Guo, Y., Ahn, M. -., Chan, A., Wang, C. -., Kang, J. -., Kim, S. -., Bello, M., Arora, R. S., Zhang, Q., He, X., Li, P., Dechaphunkul, A., Kumar, V., Kamble, K., Li, W., Kandil, A., Cohen, E. E. W., Geng, Y., Zografos, E., & Tang, P. Z. (2019). afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. Annals of oncology, 30, 1831–1839. http://access.bl.uk/ark:/81055/vdc_100099397754.0x000031